<DOC>
	<DOCNO>NCT01444378</DOCNO>
	<brief_summary>To evaluate safety effectiveness Absolute Pro® Peripheral Self-Expanding Stent System Absolute Pro® LL Peripheral Self-Expanding Stent System treatment subject atherosclerotic de novo restenotic lesion native superficial femoral artery ( SFA ) and/or native proximal popliteal artery ( PPA ) . CAUTION : Absolute Pro® Peripheral Self-Expanding Stent System Absolute Pro® LL Peripheral Self-Expanding Stent Systems investigational device . Limited Federal ( U.S. ) law investigational use .</brief_summary>
	<brief_title>Absolute Pro® MOMENTUM™</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>General Clinical 1 . Subject ≥ 18 year age . 2 . Subject legally authorize representative inform nature study , agree provision , able provide inform consent . 3 . Subject agree undergo protocolrequired followup examination requirement investigational site . 4 . Subject diagnosed moderate severe claudication ( RutherfordBecker Clinical Category 23 ) ischemic rest pain ( RutherfordBecker Clinical Category 4 ) . 5 . Female subject childbearing potential must : negative pregnancy test ( serum HCG ) within 14 day treatment ; nursing time treatment ; agree time consent use birth control participation trial . 6 . Subject life expectancy &gt; 12 month . Angiographic 1 . A single de novo restenotic [ previously treat stent , brachytherapy , laser , surgical bypass , endarterectomy ] native disease segment superficial femoral artery ( SFA ) and/or proximal popliteal artery ( PPA ) locate within follow parameter : ≥1 cm femoral bifurcation SFA . ≥3 cm proximal margin intercondylar fossa . 2 . Disease segment length visually estimate ≤ 14 cm ( 140 mm ) treat one stent . 3 . Disease segment visually estimate ≥ 50 % stenosis total occlusion . 4 . Target vessel reference diameter visually estimate ≥ 4.0 mm ≤ 7.0 mm . 5 . A patent ipsilateral iliac artery , define &lt; 50 % stenosis , confirm arteriography . 6 . At least one patent distal outflow artery ( anterior tibial , posterior tibial , peroneal ) define &lt; 50 % stenosis , provide inline circulation lower leg foot . 7 . Total occlusion length ≤ 8 cm . General Clinical 1 . Subject unable walk . 2 . Subject undergone noniliac percutaneous intervention , e.g . coronary , carotid , &lt; 30 day prior plan index procedure . 3 . Subject receive , wait list , major organ transplant . 4 . Subject diagnosed RutherfordBecker Clinical Category 5 6 either extremity . 5 . Subject diagnosed RutherfordBecker Clinical Category 0 1 target extremity ( i.e. , investigational stent place ) . 6 . Subject elevate serum creatinine &gt; 2.5 mg/dl . 7 . Subject chronic hemodialysis . 8 . Subject document suspected uncontrolled diabetes mellitus ( DM ) , unless HbA1c assess &lt; 7.0 % within 3 month prior index procedure . 9 . Subject myocardial infarction ( MI ) within previous 30 day plan index procedure . 10 . Subject stroke within previous 30 day plan index procedure and/or deficit prior stroke limit subject 's ability walk . 11 . Subject unstable angina define rest angina ECG change . 12 . Subject groin infection , acute systemic infection treat successfully currently treatment . 13 . Subject acute thrombophlebitis deep vein thrombosis either extremity . 14 . Subject unable take require antiplatelet therapy require planned procedure would necessitate discontinuation clopidogrel , prasugrel , ticagrelor ticlopidine within 30 day follow procedure . 15 . Subject medical illness ( e.g. , cancer congestive heart failure ) may cause subject noncompliant protocol requirement , confound data interpretation associate limited lifeexpectancy , i.e. , less 1 year . 16 . Subject currently participate investigational drug , biologic , device study . 17 . Subject unable understand unwilling cooperate study procedure . 18 . Subject allergic nickel , titanium , platinum , contrast medium , studyrequired medication amenable pretreatment . 19 . Subject know bleeding hypercoagulability disorder significant anemia ( Hgb &lt; 8.0 ) correct . 20 . Subject require general anesthesia procedure . 21 . Subject ischemic neuropathic ulcer either foot . 22 . Subject type amputation ipsilateral extremity , contralateral extremity amputation toe forefoot . 23 . Subject part vulnerable population , judgment investigator , unable give inform consent reason incapacity , immaturity , adverse personal circumstance lack autonomy . This may include : Individuals mental disability , person nurse home , child , impoverished person , subject emergency situation , homeless person , nomad , refugee , incapable give informed consent . Vulnerable population also may include member group hierarchical structure university student , subordinate hospital laboratory personnel , employee sponsor , member arm force , person keep detention . Angiographic 1 . Total occlusion ipsilateral iliac artery . 2 . Target extremity multilevel disease require staged procedure within 30 day procedure . 3 . Target extremity previously treat follow : surgical bypass endarterectomy . 4 . Target vessel angiographically significant ( &gt; 50 % DS ) lesion locate distal target lesion require treatment time index procedure stag procedure within 30 day procedure . 5 . Target vessel previously treat location stent , previously treat ≤ 5 cm proximal distal margin target lesion brachytherapy laser . 6 . Target lesion within adjacent aneurysm . 7 . Target lesion vessel angiographic evidence thrombus unresponsive antithrombotic therapy . 8 . Subject contralateral superficial femoral proximal popliteal artery lesion require treatment within 30 day procedure . 9 . Subject history aortic revascularization abdominal aortic aneurysm &gt; 3 cm . 10 . Subject evidence thromboembolism atheroembolism treatment ipsilateral iliac lesion . 11 . .Subject condition precludes safe access target lesion target vessel , e.g . severe calcification , excessive tortuosity . 12 . Target lesion require use reentry , ablative , cut balloon , atherectomy , similar device cross treat lesion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Atherosclerosis</keyword>
	<keyword>Claudication</keyword>
	<keyword>PAOD</keyword>
	<keyword>Peripheral Arterial Occlusive Disease</keyword>
	<keyword>Stent</keyword>
</DOC>